ARTICLE | Clinical News
Laquinimod: Phase II started
May 4, 2015 7:00 AM UTC
Teva began the double-blind, placebo-controlled, international Phase II ARPEGGIO trial to evaluate 0.6 and 1.5 mg oral laquinimod once daily in about 375 patients. Teva has exclusive, worldwide rights...